Innovita Biological Technology Co., Ltd. (SHA:688253)
57.41
-0.10 (-0.17%)
At close: Jun 2, 2026
SHA:688253 Revenue
Innovita Biological Technology had revenue of 108.81M CNY in the quarter ending March 31, 2026, a decrease of -47.43%. This brings the company's revenue in the last twelve months to 323.87M, down -40.76% year-over-year. In the year 2025, Innovita Biological Technology had annual revenue of 422.03M, down -32.08%.
Revenue (ttm)
323.87M
Revenue Growth
-40.76%
P/S Ratio
23.91
Revenue / Employee
567.21K
Employees
558
Market Cap
7.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 422.03M | -199.36M | -32.08% |
| Dec 31, 2024 | 621.39M | 143.37M | 29.99% |
| Dec 31, 2023 | 478.02M | 31.40M | 7.03% |
| Dec 31, 2022 | 446.62M | 119.71M | 36.62% |
| Dec 31, 2021 | 326.91M | -710.19M | -68.48% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Youcare Pharmaceutical Group | 2.42B |
| Aurisco Pharmaceutical | 1.68B |
| Nanjing Vazyme Biotech | 1.41B |
| Jiangxi Fushine Pharmaceutical | 1.31B |
| Shanghai Medicilon | 1.26B |
| Bio-Thera Solutions | 980.25M |
| Acrobiosystems | 887.21M |
| GemPharmatech | 830.61M |